Treatment of depression with agomelatine in psychiatric practice: Results of the VIVALDI study;Antidepressive therapie mit agomelatin in der facharztpraxis: Ergebnisse der VIVALDI-studie

Psychopharmakotherapie

Volumn 18, Issue 1, 2011, Pages 18-26

  Laux, Gerd ^a  

^a Inn Salzach Klinikum   (Germany)

Author keywords

Agomelatine; Circadian rhythms; Depression; Non interventional study; Sleep disorders

Indexed keywords

AGOMELATINE;

ARTICLE; CIRCADIAN RHYTHM; DEPRESSION; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; MAJOR CLINICAL STUDY; MEDICAL PRACTICE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; OBSERVATIONAL STUDY; OUTPATIENT; QUESTIONNAIRE; REMISSION; SLEEP WAKING CYCLE; UNSPECIFIED SIDE EFFECT;

EID: 79951607491     PISSN: 09446877     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Alonso J, Angermeyer MC, Bernert S, Bruffaerts R, et al. Prevalence of mental disorders in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESE-MeD) project. Acta Psychiatr Scand Suppl 2004;420:21-7.
2. Baghai TC, Volz HP, Möller HJ. Drug treatment of depression in the 2000s: an overview of achievements in the last 10 years and future possibilities. World J Biol Psychiatry 2006;7:198-222. (Pubitemid 44650530)
3. Fachinformation Valdoxan®, Servier Deutschland GmbH, Februar 2009.
4. Fava M. Daytime sleepiness and insomnia as correlates of depression. J Clin Psychiatry 2004;65(Suppl 16):27-32.
5. Goodwin G, Emsley R, Rembry S, Rouillon F, et al. Agomelatine prevents relapse in patients with major depressive disorder, without evidence of a discontinuation syndrome. J Clin Psychiatry 2009;70:1128-37.
6. Hale A, Corral R, Mencacci O, Saiz Ruiz J, et al. Superior antidepressant efficacy of agomelatine vs. fluoxetine in severe major depressive disorder patients: a randomised, doubleblind study. Eur Neuropsychopharmacol 2009;19(Suppl 3):S418.
7. Kasper S, Hajak G, Wulff K, Hoogendijk WJ, et al. Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double-blind comparison with sertraline. J Clin Psychiatry 2010;71:109-20.
8. Kasper S, Lemoine P. Comparative efficacy of the antidepressants agomelatine, venlafaxine and sertraline. Eur Neuropsychopharmacology 2008;18:S331-2.
9. Kennedy SH, Emsley R. Placebo-controlled trial of agomelatine in the treatment of major depressive disorder. Eur Neuropsychopharmacol 2006;16:93-100. (Pubitemid 43145814)
10. Kennedy SH, Rizvi SJ. Agomelatine in the treatment of major depressive disorder. CNS Drugs 2010;24:479-99.
11. Kennedy SH, Rizvi S, Fulton K, Rasmussen J. A double-blind comparison of sexual functioning, antidepressant efficacy, and tolerability between agomelatine and venlafaxine XR. J Clin Psychopharmacol 2008;28:329-33.
12. Laux G. Verträglichkeitsprofil von Agomelatin. Psychopharmakotherapie 2009;16(Suppl 19):11-4.
13. Laux G, Friede M. Escitalopram zur Behandlung von komorbider Angst und Depression. Ergebnisse einer Anwendungsbeobachtung. Psychopharmakotherapie 2009;16:106-13.
14. Lemoine P, Guilleminault C, Alvarez E. Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: Randomized, double-blind comparison with venlafaxine. J Clin Psychiatry 2007;68:1723-32. (Pubitemid 350247502)
15. Linden M, Baier D, Beitinger H, Kohnen R, et al. Leitlinien zur Durchführung von Anwendungsbeobachtungen (AWB) in der Psychopharmakotherapie. Nervenarzt 1994;65:638-44.
16. Lôo H, Hale A, D'Haenen H. Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT2C antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study. Int Clin Psychopharmacol 2002;17:239-47.
17. 2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. J Pharmacol Exp Ther 2003;306:954-64.
18. Möller H-J, Schnitker J. Einsatz einer modifizierten MADRS bei depressiven Patienten in einer prospektiven Kohortenstudie. Nervenarzt 2007;78:685-90. (Pubitemid 47365995)
19. Möller HJ, Friede M, Schmauß M. Behandlung der Depression mit Escitalopram. Ergebnisse einer großen Anwendungsbeobachtung. Psychopharmakotherapie 2007;14:149-56.
20. Montgomery SA, Kasper S. Severe depression and antidepressants: focus on a pooled analysis of placebo-controlled studies on agomelatine. Int Clin Psychopharmacol 2007;22:283-91. (Pubitemid 47237547)
21. Montgomery SA, Kennedy SH, Burrows GD, Lejoyeux M, et al. Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, double-blind, placebo-controlled discontinuation study. Int Clin Psychopharmacol 2004;19:271-80. (Pubitemid 39141943)
22. Nutt D, Wilson S, Paterson L. Sleep disorders as core symptoms of depression. Dialogues Clin Neurosci 2008;10:329-36.
23. 2C antagonistic properties, in major depressive disorder. Int J Neuropsychopharmacol 2007;10:661-73. (Pubitemid 47517525)
24. Popoli M. Agomelatine. Innovative pharmacological approach in depression. CNS Drugs 2009;23(Suppl 2):27-34.
25. Quera Salva MA, Vanier B, Laredo J, Hartley S, et al. Major depressive disorder, sleep EEG and agomelatine: an open-label study. Int Neuropsychopharmacol 2007;10:691-7.
26. Sobocki P, Jonsson B, Angst J, Rehnberg C. Cost of depression in Europe. J Ment Health Policy Econ 2006;9:87-98. (Pubitemid 44018376)
27. Wehr TA, Wirz-Justice A. Circadian rhythm mechanisms in affective illness and in antidepressant drug action. Pharmacopsychiatria 1992;15:31-9.
28. Winkler D, Pjrek E, Klein N, Kasper S. Escitalopram bei berufstätigen Menschen. Ergebnisse einer Anwendungsbeobachtung an 2 378 Patienten. Psychopharmakotherapie 2006;13:142-6.
29. Wirz-Justice A. Biological rhythm disturbances in mood disorders. Int Clin Psychopharmacol 2006;21(Suppl 1):S11-5.